David Witt, MD
Hematology & Oncology · Trumbull, CTNPI 1487652665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $333 and has fallen 67.0% since, to $110 in 2024. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.
Across 16 payments — averaging $45.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$149
- Novartis$110
- AstraZeneca$103
- Takeda Pharmaceuticals U.S.A., Inc.$96
- AbbVie$82
- E.r. Squibb & Sons, L.L.C.$76
- plus $113 from 4 others
Across 11 payments — averaging $3728.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$39K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Food & beverage$70096%
- Education$294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 2 | $149 |
| Novartis | 2 | $110 |
| AstraZeneca | 1 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $96 |
| AbbVie | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $76 |
| Pfizer | 4 | $52 |
| Seagen Inc. | 2 | $26 |
| Amgen | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$103
How this compares
$729 in reported general payments places this provider in the 40th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 137 | $2,205,795 |
| RevlimidLenalidomide | 76 | $1,415,998 |
| ImbruvicaIbrutinib | 36 | $545,395 |
| VenclextaVenetoclax | 31 | $345,083 |
| PomalystPomalidomide | 13 | $275,525 |
| CalquenceAcalabrutinib Maleate | 16 | $208,624 |
| EliquisApixaban | 134 | $138,556 |
| XareltoRivaroxaban | 73 | $74,760 |
| Fondaparinux Sodium | 15 | $20,842 |
| Deferasirox | 15 | $13,590 |
| Enoxaparin Sodium | 17 | $11,686 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,719 |
| Acyclovir | 93 | $1,723 |
| Hydroxyurea | 56 | $1,538 |
| Allopurinol | 146 | $1,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $82 | $345,08331 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $76 | $275,52513 claims |
| AstraZenecaCalquence | $103 | $208,62416 claims |
| PfizerEliquis | $52 | $138,556134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Trumbull
- Neal FischbachTrumbull$8K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.